UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Effect of Remote Ischaemic Conditioning in ONCology patients undergoing chemotherapy: rationale and design of the ERIC-ONC study - a single-center, blinded, randomized controlled trial

Chung, R; Maulik, A; Hamarneh, A; Hochhauser, D; Hausenloy, DJ; Walker, JM; Yellon, DM; (2016) Effect of Remote Ischaemic Conditioning in ONCology patients undergoing chemotherapy: rationale and design of the ERIC-ONC study - a single-center, blinded, randomized controlled trial. Clinical Cardiology , 39 (2) pp. 72-82. 10.1002/clc.22507. Green open access

[thumbnail of Chung_et_al-2016-Clinical_Cardiology.pdf]
Preview
Text
Chung_et_al-2016-Clinical_Cardiology.pdf - Published Version

Download (770kB) | Preview

Abstract

Cancer survival continues to improve, and thus cardiovascular consequences of chemotherapy are increasingly important determinants of long-term morbidity and mortality. Conventional strategies to protect the heart from chemotherapy have important hemodynamic or myelosuppressive side effects. Remote ischemic conditioning (RIC) using intermittent limb ischemia-reperfusion reduces myocardial injury in the setting of percutaneous coronary intervention. Anthracycline cardiotoxicity and ischemia-reperfusion injury share common biochemical pathways in cardiomyocytes. The potential for RIC as a novel treatment to reduce subclinical myocyte injury in chemotherapy has never been explored and will be investigated in the Effect of Remote Ischaemic Conditioning in Oncology (ERIC-ONC) trial (clinicaltrials.gov NCT 02471885). The ERIC-ONC trial is a single-center, blinded, randomized, sham-controlled study. We aim to recruit 128 adult oncology patients undergoing anthracycline-based chemotherapy treatment, randomized in a 1:1 ratio into 2 groups: (1) sham procedure or (2) RIC, comprising 4, 5-minute cycles of upper arm blood pressure cuff inflations and deflations, immediately before each cycle of chemotherapy. The primary outcome measure, defining cardiac injury, will be high-sensitivity troponin-T over 6 cycles of chemotherapy and 12 months follow-up. Secondary outcome measures will include clinical, electrical, structural, and biochemical endpoints comprising major adverse cardiovascular clinical events, incidence of cardiac arrhythmia over 14 days at cycle 5/6, echocardiographic ventricular function, N-terminal pro-brain natriuretic peptide levels at 3 months follow-up, and changes in mitochondrial DNA, micro-RNA, and proteomics after chemotherapy. The ERIC-ONC trial will determine the efficacy of RIC as a novel, noninvasive, nonpharmacological, low-cost cardioprotectant in cancer patients undergoing anthracycline-based chemotherapy.

Type: Article
Title: Effect of Remote Ischaemic Conditioning in ONCology patients undergoing chemotherapy: rationale and design of the ERIC-ONC study - a single-center, blinded, randomized controlled trial
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/clc.22507
Publisher version: http://dx.doi.org/10.1002/clc.22507
Additional information: © 2016 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Pre-clinical and Fundamental Science
URI: https://discovery.ucl.ac.uk/id/eprint/1476613
Downloads since deposit
169Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item